PDCD1 and neoplasm: Studies conducted on PD-1 positive Tregs indicated that these cells are capable of predicting the clinical efficacy of PD-1 blockade therapies better than its ligand, PD-L1, nor the mutational burden observed within the tumor microenvironment [113].